Molecular Biology Research Technique

AviadoBio Secures Option to Develop Rare Eye Disease Gene Therapy UGX-202 in $413 Million Deal with China’s UgeneX

2 weeks ago talkbio0Tagged AviadoBio, China, gene therapy, Optogenetics, Retinitis Pigmentosa, UgeneX, UGX-202

AviadoBio; UgeneX; UGX-202; optogenetics; gene therapy; retinitis pigmentosa; China; $413 million deal

AviadoBio Secures Option to UgeneX’s UGX-202 Gene Therapy for Retinal Disease

2 weeks ago talkbio0Tagged AviadoBio, Clinical Development, Dependovirus, gene therapy, Optogenetics, Retinal Diseases, Retinitis Pigmentosa, UGX-202

AviadoBio; UgeneX Therapeutics; UGX-202; retinitis pigmentosa; gene therapy; optogenetics; adeno-associated virus (AAV); exclusive option; retinal disease; clinical development

Meeting on the Mesa 2025 Arrives Amid Mixed Signals for Cell and Gene Therapy Sector

3 weeks ago talkbio0Tagged Advanced therapies, Alternative, Cells, Clinical Trials, commercialization, Gene Modification, gene therapy, Industry, meeting, MESA, partnerships, payment, Phoenix Arizona, regulatory challenges, RNA, Messenger, Study models

Cell and gene therapy; Meeting on the Mesa; Commercialization; Clinical trials; Advanced therapies; Industry partnerships; Regulatory challenges; Phoenix Arizona; mRNA; Gene editing; Alternative payment models

AstraZeneca and SOPHiA GENETICS Expand AI-Powered Cancer Testing Collaboration

1 month ago talkbio0Tagged Artificial Intelligence, AstraZeneca, cancer testing, High-Throughput Nucleotide Sequencing, Malignant neoplasm of breast, Malignant neoplasm of prostate, PIK3CA/AKT1/PTEN pathway, Precision Medicine, real-world evidence, SOPHiA GENETICS

AstraZeneca; SOPHiA GENETICS; AI; cancer testing; breast cancer; prostate cancer; next generation sequencing (NGS); PIK3CA/AKT1/PTEN pathway; real-world evidence; precision medicine

Editas Medicine Reboots With Cholesterol Gene Therapy (EDIT-401) as Lead Asset

2 months ago talkbio0Tagged Clinical Development, EDIT-401, Editas Medicine, Gene Modification, gene therapy, Hyperlipidemia, in vivo, LDL Cholesterol Lipoproteins, LDLR gene, strategic pivot

Editas Medicine; EDIT-401; gene therapy; hyperlipidaemia; LDL cholesterol; LDLR gene; in vivo gene editing; strategic pivot; clinical development

Recent Advances for Confident Cell Line Transfer

2 months ago talkbio0Tagged Biomechanical compliance, cell line development, Cell Therapy, cell transfer, clone stability, Electroporation, Guanosine Monophosphate, quality assurance, Transfection

cell line development; cell transfer; clone stability; electroporation; transfection; quality assurance; GMP compliance; cell therapy

Eli Lilly Pays $1B Upfront to Acquire Verve Therapeutics, Expanding Cardiovascular Gene Editing Portfolio

4 months ago talkbio0Tagged Acquisition, Cardiovascular Diseases, eli lilly, Gene Modification, Heart Diseases, PCSK9 protein, human, VERVE-102

Eli Lilly; Verve Therapeutics; gene editing; cardiovascular disease; acquisition; PCSK9; VERVE-102; biotech; heart disease

Analysts Downplay Intellia Adverse Event, but Gene Therapy Safety Remains Under Scrutiny

5 months ago talkbio0Tagged Adverse event, ATTR-CM, Event, Gene Modification, gene therapy, Intellia, liver transaminase, MAGNITUDE trial, Response process, Safety, Stock Decline

Intellia Therapeutics; gene therapy; safety event; adverse event; MAGNITUDE trial; liver transaminase; stock decline; ATTR-CM; gene editing; analyst response

Post-Hoc: AI bio needs to heed the overhyped history of CRISPR

5 months ago talkbio0Tagged Artificial Intelligence, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, overhype, reproductive health biotech

CRISPR; AI in biotech; overhype; gene editing; reproductive health biotech

CRISPR Therapeutics Partners with Sirius for siRNA Therapies, Expanding Beyond Gene Editing

5 months ago talkbio0Tagged Anticoagulants, biotech partnerships, Cardiovascular Diseases, Clustered Regularly Interspaced Short Palindromic Repeats, Factor XI, Gene Modification, RNA, Small Interfering, Sirius, SRSD107, thrombotic disease

CRISPR Therapeutics; Sirius Therapeutics; siRNA; gene editing; SRSD107; cardiovascular diseases; thrombotic disease; biotech partnerships; Factor XI; anticoagulant therapies